Kiniksa Pharmaceuticals Ltd - Class A logo

KNSA

Kiniksa Pharmaceuticals Ltd - Class A

$11.7

Earnings Summary

Revenue
$32.19Mn
Net Profits
$-25.21Mn
Net Profit Margins
-78.32%

Highlights

Revenue:

Kiniksa Pharmaceuticals Ltd - Class A’s revenue jumped +Inf% since last year same period to $32.19Mn in the Q1 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd - Class A has generated 71.72% jump in its revenue since last 3-months.

Net Profits:

Kiniksa Pharmaceuticals Ltd - Class A’s net profit jumped 49.05% since last year same period to $-25.21Mn in the Q1 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd - Class A has generated 30.61% jump in its net profits since last 3-months.

Net Profit Margins:

Kiniksa Pharmaceuticals Ltd - Class A’s net profit margin jumped NaN% since last year same period to -78.32% in the Q1 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd - Class A has generated 59.59% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kiniksa Pharmaceuticals Ltd - Class A post its latest quarter earnings

EPS Estimate Current Quarter
-0.39
EPS Estimate Current Year
-0.39

Highlights

EPS Estimate Current Quarter:

Kiniksa Pharmaceuticals Ltd - Class A’s earning per share (EPS) estimates for the current quarter stand at -0.39 - a 11.36% jump from last quarter’s estimates.

EPS Estimate Current Year:

Kiniksa Pharmaceuticals Ltd - Class A’s earning per share (EPS) estimates for the current year stand at -0.39.

Key Ratios

Key ratios of the Kiniksa Pharmaceuticals Ltd - Class A post its Q2 2022 earnings

Earning Per Share (EPS)
-0.29

Highlights

Earning Per Share (EPS):

Kiniksa Pharmaceuticals Ltd - Class A’s earning per share (EPS) jumped 52.46% since last year same period to -0.29 in the Q2 2022. This indicates that the Kiniksa Pharmaceuticals Ltd - Class A has generated 52.46% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.41
-0.36
12.2%
2022-08-03
-0.44
-0.29
34.09%

Company Information

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases.

Organisation
Kiniksa Pharmaceuticals Ltd - Class A
Employees
168
Industry
Health Technology